We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Polymer-Based Rapid Test Visually Differentiates Tumor Cells

By LabMedica International staff writers
Posted on 18 Jan 2016
Print article
Image: A cell phone camera is sufficient to examine tissue samples for tumor cells (Photo courtesy of Fraunhofer IAP).
Image: A cell phone camera is sufficient to examine tissue samples for tumor cells (Photo courtesy of Fraunhofer IAP).
A polymer-based rapid test has been developed which visually differentiates tumor cells from healthy cells in a tissue section through the use of a simple microscope. Surgeons can already use the test in the operating room which saves time and expenses.

Antibodies combat viruses and bacteria and they also attach themselves to cancer cells in a typical, characteristic way. This property has been used to detect cancer cells in tissue samples and such rapid tests can already be applied by surgeons during operations, within a few minutes and without expensive equipment.

Scientists at the Fraunhofer Institute for Applied Polymer Research (IAP; Potsdam, Germany) have developed a polymer-based rapid test which visually differentiates tumor cells from healthy cells in a tissue section through the use of a simple microscope. Surgeons can already use the test in the operating room. This saves time and expenditures. Studies have shown that receptors sit on tumor cells, and certain specific antibodies attach to these receptors: for example, estrogen antibodies on breast carcinomas. Using this "immunodiagnostic" method, the surgeon only needs a few minutes to make sure that all the diseased tissue has been removed. Once placed on the tissue sample, the antibodies search independently for their counterpart, the receptors, which are distinctive for them.

For reasons of reliability, a cross test characteristically dyes the healthy cells in the next step. Once neither of the two tests detects any more tumor cells, the surgeon can conclude the operation as he has cut out all of the diseased cells. The scientists are working to make the color contrasts between healthy and diseased tissue cells more clearly visible. Joachim Storsberg, PhD, head of department Functional Polymers for Medical Technology, said, “Locating tumors accurately in tissue sections is not easy. It's easy to distinguish diseased from healthy tissue at the core of the cancerous ulcer, but not around the edges: tumors spread out asymmetrically.”

Related Links:

Fraunhofer Institute for Applied Polymer Research


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.